Understand the source comparison
DSIP FDA Approved Status: Comparison
Semaglutide (Wegovy, Ozempic) FDA approved (2017, 2021) Type 2 diabetes, obesity Phase III (STEP program, SUSTAIN program) cGMP pharmaceutical-grade Fully approved prescription medication with documented safety profile across 68-week trials involving 16,000+ p
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Semaglutide (Wegovy, Ozempic)
- FDA approved (2017, 2021)
- Type 2 diabetes, obesity
- Phase III (STEP program, SUSTAIN program)
- cGMP pharmaceutical-grade
- Fully approved prescription medication with documented safety profile across 68-week trials involving 16,000+ participants
- Liraglutide (Saxenda, Victoza)
- FDA approved (2010, 2014)
- Phase III (SCALE program, LEAD program)
- Approved GLP-1 agonist with established cardiovascular safety data from the LEADER trial (9,340 participants)
- DSIP (delta sleep-inducing peptide)
- Not approved—research chemical only
- None (no therapeutic indication)
- Phase I/II exploratory (discontinued in 1990s)
- Research-grade synthesis (no cGMP requirement)
- DSIP has never progressed beyond early investigational trials and remains outside the FDA drug approval framework entirely
- BPC-157
- Preclinical animal studies only
- No human clinical trials registered; sold as research peptide with no FDA oversight of manufacturing or therapeutic claims
- Tirzepatide (Mounjaro, Zepbound)
- FDA approved (2022, 2023)
- Phase III (SURPASS program, SURMOUNT program)
- Dual GIP/GLP-1 agonist approved after demonstrating mean body weight reduction of 20.9% at 72 weeks in Phase III trials